Chronic heart failure
349 results
50 - 149
Aliskiren not beneficial for chronic heart failure (ATMOSPHERE)
Pharmacological interventions for heart failure in people with chronic kidney disease- Erythropoiesis‐stimulating agents for anaemia in chronic heart failure patients
- Ivabradine as adjuvant treatment for chronic heart failure
- Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
- IV iron improves symptoms in chronic heart failure patients with iron deficiency
Chronic heart failure - Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
- Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
- Phosphodiesterase III inhibitors for heart failure
- Increased pulmonary blood pressure: pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
- Diuretics for heart failure: Cochrane systematic review
- Acute heart failure and pulmonary oedema
- Nitrates for acute heart failure syndromes
- BNP-guided therapy decreases heart failure mortality (BATTLESCARRED)
- Sertraline ineffective for depression associated with heart failure
- New "-flozin" type 2 diabetes treatments improve outcomes in patients with heart failure, with or without diabetes
- Point-of-care BNP testing may be helpful to rule out heart failure
- Exercise stress test
- Antioxidants for adults with chronic kidney disease
- Chronic coronary syndrome (coronary heart disease)
- Intravenous iron therapy improves quality of life in iron-deficient adults with heart failure
- Improved decongestion with the addition of acetazolamide to intravenous loop diuretics for acute heart failure
- LCZ696 (sacubitril/valsartan) for patients with heart failure
- Sotagliflozin reduces hospitalizations and urgent visits for heart failure, but has no mortality benefit (SCORED)
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- Carvedilol not beneficial for children and adolescents with heart failure
- Prolonged cough in adults
- Dyspnoea
- Glucagon‐like peptide 1 (GLP‐1) receptor agonists for people with chronic kidney disease and diabetes
- Dapagliflozin reduces mortality and hospitalization rates for patients with mild heart failure and reduced ejection fraction
- Interpreting BNP in patients with a history of HF
- SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status
- BNP-guided tx decreases CHF mortality
- Leg oedema
- Minimal, if any, cardiovascular benefit from intravenous iron for adults with heart failure and iron deficiency
- Aldosterone receptor antagonists spironolactone and eplerenone for congestive heart failure
- Long-term adverse effects of antineoplastic agents
- Hyperkalaemia
- Rhythm control improves quality of life in patients with CHF and AF
- Safe use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Hyperglycaemic hyperosmolar syndrome
- Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
- Drug treatment for hypertension
- Remote digital monitoring for selected chronic diseases in primary health care
- Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
- No benefit with torsemide over furosemide for posthospitalization treatment of heart failure (TRANSFORM-HF)
- Darbepoetin alfa does not improve HF outcomes
- Pneumonia
- Respiratory failure
- Acute cardiovascular events are common in patients hospitalized with influenza
- Rosuvastatin has no effect on clinical outcomes in CHF
- Cardioselective beta‐blockers for chronic obstructive pulmonary disease
- Beta-blockers don't decrease mortality in patients with AF + CHF
- Non‐invasive positive pressure ventilation for central sleep apnoea in adults
- Mitral regurgitation
- Antiplatelet agents for chronic kidney disease
- Organ transplant recipient in primary health care
- Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease
- Hypertension in elderly patients
- Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
- Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
- Structured telephone support or non‐invasive telemonitoring for patients with heart failure
- Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease